KIR3DL2 may represent a novel therapeutic target in aggressive systemic peripheral T-cell lymphoma-Reference-Cited by-同舟云学术

KIR3DL2 may represent a novel therapeutic target in aggressive systemic peripheral T-cell lymphoma

Published:2023-05-11 Issue:10 Volume:108 Page:2830-2836
ISSN:1592-8721
Container-title:Haematologica
language:
Short-container-title:haematol

Author:

Decroos Amandine,Cheminant Morgane,Bruneau Julie,Carras Sylvain,Parinet Vincent,Pelletier Laura,Lacroix Laetitia,Martin Nadine,Giustiniani Jérôme,Lhermitte Ludovic,Asnafi Vahid,Battistella Maxime,Lemonnier François,De Leval Laurence,Sicard Hélène,Bonnafous Cécile,Gauthier Laurent,Genestier Laurent,Caruso Stefano,Gaulard Philippe,Hermine Olivier,Ortonne Nicolas

Publisher

Ferrata Storti Foundation (Haematologica)

Subject

Hematology

Reference15 articles.

1. Bagot M, Porcu P, Marie-Cardine A. IPH4102, a first-inclass anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. Lancet Oncol. 2019; 20(8):1160-1170.

2. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol. 2005; 5(3):201-214.

3. Ortonne N, Huet D, Gaudez C. Significance of circulating T-cell clones in Sezary syndrome. Blood. 2006; 107(10):4030-4038.

4. Battistella M, Leboeuf C, Ram-Wolff C. KIR3DL2 expression in cutaneous T-cell lymphomas: expanding the spectrum for KIR3DL2 targeting. Blood. 2017; 130(26):2900-2902.

5. Cheminant M, Lhermitte L, Bruneau J. KIR3DL2 contributes to the typing of acute-type adult T-cell leukemia and is a potential therapeutic target. Blood. 2022; 140(13):1522-1532.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the role of KIR3DL2 on NK cells in hepatocellular carcinoma and its potential prognostic implications;iScience;2024-09

2. Investigating the role of killer cell immunoglobulin‐like receptors and human leukocyte antigen genetic variants in hepatitis C virus infection;Journal of Medical Virology;2024-07

3. Aggressive T‐cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management;American Journal of Hematology;2024-02-02

4. How molecular advances may improve the diagnosis and management of PTCL patients;Frontiers in Oncology;2023-06-23